Clinical Medicine Journal
Articles Information
Clinical Medicine Journal, Vol.1, No.2, Jun. 2015, Pub. Date: Apr. 22, 2015
A Retrospective Study on Correlation between Sentinel Node Biopsy, Axillary Node Sampling and Type and Grade of Tumour in Breast Cancer Patients
Pages: 30-33 Views: 1266 Downloads: 373
[01] S. Gopalswamy, Department of Breast Surgery, Royal Cornwall Hospitals, Truro, UK.
[02] M. Alchalabi, Department of Breast Surgery, Royal Cornwall Hospitals, Truro, UK.
Lymph node metastases are the most significant prognostic factors in patients with breast carcinoma. A lymph node defined as sentinel lymph node (SLN) would be the first to receive tumoral drainage. A positive sentinel lymph node (SLN) biopsy is followed by an axillary lymph node clearance (ANC). In sentinel lymph node negative cases, the risk of positive non-sentinel lymph nodes (ANS: Axillary node sampling) is very low. The aim of this retrospective study was to determine the rate of sentinel lymph node (SLN) positivity, number of SLN harvested, grade, size and type of the tumour in SLN positive cases and the percentage of ANS positivity, in addition to ANC complications. Patients and Methods— Between January 2009 and May 2010, 223 female patients with breast cancer who underwent wide local excision and the SLN biopsy were reviewed. 222 patients of them had SLN biopsy. Results— SLNs were positive in 44 of 223 (19.82%) The mean number of SLNs removed was 2.35; the median was 2. ANSs were positive in 5 of 117 cases. The mean number of ANSs removed was 2.25, the median was 2. The Commonest grade of tumour in cases of positive SLN was grade 2. The Commonest type of tumour was invasive ductal carcinoma (73.99%) followed by invasive lobular carcinoma (10.3%).The complications of ANC were seen in 25 patients (60.97%) out of 41 patients Conclusion—SLN positivity was 19.82% and the median SLN collected was 2. ANS positivity was 4.3%. The commonest grade was grade2. The Median size of tumour with positive SLN is 17mm.
Sentinel Lymph Node (SLN), Axillary Node Sampling (ANS), Axillary Node Clearance (ANC), Tumour Grade
[01] Singh Ranger G, Mokbel K: The evolving role of sentinel lymph node biopsy for breast cancer. [Review] Eur J Surg Oncol 29(5):423–425, 2003.
[02] Giuliano AE, Haigh PI, Brennan MB, et al: Prospective o b s e rvational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18(13): 2553–2559, 2000.
[03] Shimazu K, Tamaki Y, Taguchi T, et al: Comparison between periareolar and peritumoral injection of radiotracer for sentinel lymph node biopsy in patients with breast cancer. Surgery 131(3): 277–286, 2002.
[04] Ve ronesi U, Galimberti V, Zurrida S, et al: Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 37(4): 454–458, 2001.
[05] K. Khalifa, B. Pereira, V.A. Thomas, K. Mokbel: The Accuracy of Intraoperative frozen Section Analysis of the Sentinel Lymph Nodes During Breast Cancer Surgery.Int J Fertil, 49(5), 2004.
[06] Wong SL, Edwards MJ, Chao C, et al: The effect of prior breast biopsy and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 9(3):272–277, 2002.
[07] Chung MH, Ye W, Giuliano AE: Role for sentinel lymph node dissection in the management of large (> or = 5c) invasive breast cancer. Ann Surg Oncol 8(9):688–692, 2001.
[08] Mertz L, Masthelin C, Marin C, et al: Subareolar injection of 99m-Tc sulphur colloid for sentinel node identification in multifocal invasive breast cancer. Bull Cancer 86(11):939–945, 1999.
[09] Stearns V, CA, Slack R, Penannen MF, et al: Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably re p resent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235–242, 2002.
[10] Brady EW: Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. B reast J 8(2):97–100, 2002.
[11] Haigh PI, Hansen NM, Qi K, et al: Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 7(1):21–27, 2000.
[12] Port ER, Fey J, Gemignani ML, et al: Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 195(2):167–172, 2002.
[13] Gould EA, Winship T, Philbin PH, Hyland Kerr H. Observations on a "sentinel node" in cancer of the parotid. Cancer. 1960;13:77–78.
[14] Cabanas RM. An approach to the treatment of penile carcinoma. Cancer 1977;39:456–466.
[15] Ciatto S, Rosselli Del Turco M, Bonardi R, et al. Non-palpable lesions of the breast detected by mammography: review of 1182 consecutive histologically confirmed cases. Eur J Cancer. 1994;30:40–44.
[16] Cady B. New era in breast cancer: impact of screening on disease presentation. Surg Oncol Clin N Am. 1997;6:195–202.
[17] Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187.
[18] Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol. 1990;16.;127–133.
[19] Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999;86:449–462.
[20] Ruffin WK, Stacey-Clear A, Younger J, Hover HC. Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg. 1995;180:245–251.
[21] Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol. 1997;66:7–10.
[22] Burke HIB, Hutter RVP, Henson DE. Breast carcinoma. In: Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH, eds. Prognostic Factors in Cancer Berlin, Germany: Springer Verlag; 1995:165–176.
[23] Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and for how long?—another operation soon to be extinct [editorial]? J Surg Oncol. 1991;48:217–219.
[24] Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–399.
[25] Viale G, Bosari S, Mazzarol G, et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer. 1999;85:2433–2438.
[26] Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K: A prognostic index in primary breast cancer. Br J Cancer 1982, 45:361-365.
[27] Greenhough RB: Varying degree of malignancy in cancer of the breast. J Cancer Res 1925, 9:452-463.
[28] Harris JR, Connolly JL, Schnitt SJ, Silen W: The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg 1984, 201:164-169.
[29] Fentiman IS (Ed): Biopsy In Detection and treatment of breast cancer. London: Martin Dunitz Ltd; 1998:71-83.
MA 02210, USA
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - 2017 American Institute of Science except certain content provided by third parties.